Federated Hermes’s Karyopharm Therapeutics KPTI Stock Holding History

Federated Hermes’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,574	Closed	-$131K	–	2196
2022 Q4	$131K	Buy	+2,574	New	+$178K	﹤0.01%	1612
2022 Q3	–	Sell	-329	Closed	-$22K	–	2191
2022 Q2	$22K	Buy	+329	New	+$30.2K	﹤0.01%	1756
2020 Q2	–	Sell	-1,721	Closed	-$496K	–	2309
2020 Q1	$496K	Sell	1,721 -52,763	-97%	-$14.6M	﹤0.01%	1381
2019 Q4	$15.7M	Buy	+54,484	New	+$11.8M	0.03%	481
2019 Q2	–	Sell	-6,119	Closed	-$536K	–	2190
2019 Q1	$536K	Sell	6,119 -13,441	-69%	-$1.49M	﹤0.01%	1429
2018 Q4	$2.75M	Sell	19,560 -164	-0.8%	-$27.7K	0.01%	927
2018 Q3	$5.04M	Buy	19,724 +19,561	+12,001%	+$5.41M	0.01%	802
2018 Q2	$42K	Buy	163 +149	+1,064%	+$36.9K	﹤0.01%	1713
2018 Q1	$3K	Buy	+14	New	+$2.79K	﹤0.01%	2029

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Federated Hermes's KPTI Position: Q1 2023 in Review

Federated Hermes sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 2,574 shares — an estimated $131K sold.

Federated Hermes first reported a position in KPTI in Q1 2018 and held it in 9 quarters. The position peaked at $15.7M in Q4 2019. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

Federated Hermes reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
Federated Hermes sold 2,574 Karyopharm Therapeutics shares in Q1 2023, an estimated $131K.
Federated Hermes first reported a position in Karyopharm Therapeutics in Q1 2018 and held it in 9 quarters.
Federated Hermes's Karyopharm Therapeutics position peaked at $15.7M in Q4 2019.
129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.